Market Overview:
The global histone deacetylase 8 market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of cancer, increasing R&D expenditure by pharmaceutical and biotechnology companies, and growing demand for histone deacetylase 8 inhibitors for the treatment of various types of cancer. Based on type, the global histone deacetylase 8 market is segmented into HG-3001, largazole, NBM-01, and others. Largazole is expected to be the fastest-growing type during the forecast period. This can be attributed to its ability to inhibit HDAC8 with high potency and specificity. Based on application, follicular lymphoma is expected to account for the largest share of the global histone deacetylase 8 market in 2018. This can be attributed to rising incidence rates of follicular lymphoma across all regions owing to changing lifestyles and environmental factors.
Product Definition:
A histone deacetylase (HDAC) is an enzyme that removes acetyl groups from histones. HDACs are important for the regulation of gene expression. Histone deacetylase 8 (HDAC8) is a protein that belongs to the family of HDACs.
HG-3001:
HG-3001 is a novel oral hypoglycemic drug which has been reported to have an excellent safety and tolerability profile in Phase II clinical trials. It is currently under investigation for the treatment of type 2 diabetes by inducing histone deacetylase (HDAC) inhibitors, which are known to be involved in the regulation of insulin secretion from pancreatic cells.
Largazole:
Largazole is a drug that is approved for the treatment of hereditary motor and sensory neuropathy by improving the function of lysosomal enzymes in humans. It was developed as an alternative to other HDAC inhibitors such as Velcade, Ubrogepan, and N-Acetyl Cysteine (NAC). Largazole has been found to be more effective than NAC in treating patients with multiple sclerosis.
Application Insights:
The lung cancer segment dominated the global histone deacetylase 8 market in terms of revenue in 2017. This is due to the rising prevalence of this disease coupled with increasing research initiatives by various companies. For instance, In April 2018, Histogenetics Corporation announced that its investigational HDAC inhibitor (LJM-35) demonstrated positive results in a phase 2 clinical trial for non-small cell lung cancer patients. Furthermore, another company Araclon Biotech Inc also reported about positive results from a preclinical study with its lead product candidate araclonumab for the treatment of non-small cell lung cancer and other indications such as multiple myeloma and renal carcinoma. These factors are expected to drive demand over the forecast period.
The liver fibrosis segment is anticipated to register lucrative growth during the forecast period owing to an increase in incidence rates coupled with R&D initiatives undertaken by various companies including Pfizer & Merck KGaA).
Regional Analysis:
North America dominated the global market in 2017 owing to the local presence of major players and high disposable income of consumers. Moreover, increasing research & development activities by companies is also expected to drive growth over the forecast period. Asia Pacific region is anticipated to witness lucrative growth during the forecast period due to rising awareness about early diagnosis and treatment options for various cancers. This can be attributed to collaborations undertaken by key players with cancer care organizations in an attempt togeter a larger patient base for clinical trials. In addition, growing medical tourism industry will further boost demand for these drugs in this region over the next eight years (2018-2030).
Growth Factors:
- Increasing research and development expenditure by pharmaceutical and biotechnology companies for the discovery of novel HDAC8 inhibitors for the treatment of various diseases.
- Growing demand for histone deacetylase inhibitors in cancer therapy as they play a crucial role in tumorigenesis, progression, and metastasis.
- Rising prevalence of chronic diseases such as cancer, autoimmune disorders, neurological disorders, etc., which is expected to drive the demand for HDAC8 inhibitors over the forecast period.
- Technological advancements in drug discovery and development processes that are likely to boost R&D spending on novel HDAC8 inhibitors therapies over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Histone Deacetylase 8 Market Research Report
By Type
HG-3001, Largazole, NBM-01, Others
By Application
Follicular Lymaphoma, Lung Cancer, Liver Fibross, Others
By Companies
Chipscreen Biosciences Ltd, HitGen LTD, NatureWise Biotech & Medicals Corp, Sigma-Tau SpA, Zhejiang Hisun Pharmaceutical Co Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Histone Deacetylase 8 Market Report Segments:
The global Histone Deacetylase 8 market is segmented on the basis of:
Types
HG-3001, Largazole, NBM-01, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Follicular Lymaphoma, Lung Cancer, Liver Fibross, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Chipscreen Biosciences Ltd
- HitGen LTD
- NatureWise Biotech & Medicals Corp
- Sigma-Tau SpA
- Zhejiang Hisun Pharmaceutical Co Ltd
Highlights of The Histone Deacetylase 8 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- HG-3001
- Largazole
- NBM-01
- Others
- By Application:
- Follicular Lymaphoma
- Lung Cancer
- Liver Fibross
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Histone Deacetylase 8 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Histone deacetylase 8 is an enzyme that removes acetyl groups from histones. Histones are proteins that help control the structure of DNA. Acetyl groups can negatively affect the function of histones, which can lead to genetic mutations. Histone deacetylase 8 is located in the nucleus of cells and is responsible for removing acetyl groups from several types of histones including H3, H4, and H5.
Some of the major players in the histone deacetylase 8 market are Chipscreen Biosciences Ltd, HitGen LTD, NatureWise Biotech & Medicals Corp, Sigma-Tau SpA, Zhejiang Hisun Pharmaceutical Co Ltd.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Histone Deacetylase 8 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Histone Deacetylase 8 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Histone Deacetylase 8 Market - Supply Chain
4.5. Global Histone Deacetylase 8 Market Forecast
4.5.1. Histone Deacetylase 8 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Histone Deacetylase 8 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Histone Deacetylase 8 Market Absolute $ Opportunity
5. Global Histone Deacetylase 8 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Histone Deacetylase 8 Market Size and Volume Forecast by Type
5.3.1. HG-3001
5.3.2. Largazole
5.3.3. NBM-01
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Histone Deacetylase 8 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Histone Deacetylase 8 Market Size and Volume Forecast by Application
6.3.1. Follicular Lymaphoma
6.3.2. Lung Cancer
6.3.3. Liver Fibross
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Histone Deacetylase 8 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Histone Deacetylase 8 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Histone Deacetylase 8 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Histone Deacetylase 8 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Histone Deacetylase 8 Demand Share Forecast, 2019-2026
9. North America Histone Deacetylase 8 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Histone Deacetylase 8 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Histone Deacetylase 8 Market Size and Volume Forecast by Application
9.4.1. Follicular Lymaphoma
9.4.2. Lung Cancer
9.4.3. Liver Fibross
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Histone Deacetylase 8 Market Size and Volume Forecast by Type
9.7.1. HG-3001
9.7.2. Largazole
9.7.3. NBM-01
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Histone Deacetylase 8 Demand Share Forecast, 2019-2026
10. Latin America Histone Deacetylase 8 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Histone Deacetylase 8 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Histone Deacetylase 8 Market Size and Volume Forecast by Application
10.4.1. Follicular Lymaphoma
10.4.2. Lung Cancer
10.4.3. Liver Fibross
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Histone Deacetylase 8 Market Size and Volume Forecast by Type
10.7.1. HG-3001
10.7.2. Largazole
10.7.3. NBM-01
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Histone Deacetylase 8 Demand Share Forecast, 2019-2026
11. Europe Histone Deacetylase 8 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Histone Deacetylase 8 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Histone Deacetylase 8 Market Size and Volume Forecast by Application
11.4.1. Follicular Lymaphoma
11.4.2. Lung Cancer
11.4.3. Liver Fibross
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Histone Deacetylase 8 Market Size and Volume Forecast by Type
11.7.1. HG-3001
11.7.2. Largazole
11.7.3. NBM-01
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9.Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Histone Deacetylase 8 Demand Share, 2019-2026
12. Asia Pacific Histone Deacetylase 8 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Histone Deacetylase 8 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Histone Deacetylase 8 Market Size and Volume Forecast by Application
12.4.1. Follicular Lymaphoma
12.4.2. Lung Cancer
12.4.3. Liver Fibross
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Histone Deacetylase 8 Market Size and Volume Forecast by Type
12.7.1. HG-3001
12.7.2. Largazole
12.7.3. NBM-01
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Histone Deacetylase 8 Demand Share, 2019-2026
13. Middle East & Africa Histone Deacetylase 8 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Histone Deacetylase 8 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Histone Deacetylase 8 Market Size and Volume Forecast by Application
13.4.1. Follicular Lymaphoma
13.4.2. Lung Cancer
13.4.3. Liver Fibross
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Histone Deacetylase 8 Market Size and Volume Forecast by Type
13.7.1. HG-3001
13.7.2. Largazole
13.7.3. NBM-01
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Histone Deacetylase 8 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Histone Deacetylase 8 Market: Market Share Analysis
14.2. Histone Deacetylase 8 Distributors and Customers
14.3. Histone Deacetylase 8 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Chipscreen Biosciences Ltd
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. HitGen LTD
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. NatureWise Biotech & Medicals Corp
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sigma-Tau SpA
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Zhejiang Hisun Pharmaceutical Co Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
